Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty

Sponsor
Daniela Francescato Veiga (Other)
Overall Status
Recruiting
CT.gov ID
NCT04079686
Collaborator
(none)
146
1
2
56.9
2.6

Study Details

Study Description

Brief Summary

Setting: Translacional Surgery Graduation Program - Universidade Federal de São Paulo and Hospital das Clínicas Samuel Libânio - Universidade do Vale do Sapucaí. Background: Breast reduction is one of the most performed plastic surgery procedures. Antibiotics are widely prescribed, on an empirical basis, to prevent surgical site infections. However, there is a lack of evidence to support its use. Objective: To compare the influence of the use of prophylatic antibiotics as a single dose or for 24 hours on surgical site infection rates following reduction mammaplasty. Methods: Randomized trial of non-inferiority, with two parallel groups, double blinded. A total of 146 breast hypertrophy patients, with reduction mammaplasty already scheduled, will be enrolled. Patients will be randomly allocated to group A, that will receive antibiotics only at the anesthesia induction (n=73), or to group B, that will receive antibiotics at the anesthesia induction and for 24 hours (n=73). None of the patients will receive antibiotics after hospital discharge. Patients will be followed-up weekly, for 30 days, regarding surgical site infection. The Centers for Disease Control and Prevention criteria will be applied. A statistical analysis of the data will be performed.

Condition or Disease Intervention/Treatment Phase
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
146 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Single Dose Versus 24 Hours Antibiotic Prophylaxis in Reduction Mammaplasty: a Randomized Clinical Trial
Actual Study Start Date :
Aug 5, 2019
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cephazolin

Patients will receive antibiotics (1g cephazolin) intravenously at the anesthestic induction and every 6 hours for 24 hours

Drug: Cephazolin
Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.

Placebo Comparator: Sterile saline

Patients will receive antibiotics (cephazolin) only at the anesthesia induction, and sterile saline intravenously every 6 hours for 24 hours

Other: Sterile saline
Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.

Outcome Measures

Primary Outcome Measures

  1. Number of patients with surgical site infection (SSI) [30 days]

    Patients will be monitored for the occurrence of SSI once weekly during the first 30 days following hospital discharge by a single surgeon who is blinded to their treatment group. SSI will be evaluated based on the definition adopted by the Centers for Disease Control and Prevention.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 and 60 years of age

  • body mass index (BMI) between 19 and 30 kg/m2

  • breast hypertrophy according to the criteria of Sacchini et al. and Franco and Rebello

Exclusion Criteria:
  • patients who had previously undergone another surgical procedure of the breast

  • patients who have been diagnosed with a breast pathology

  • smokers

  • patients who had a child or breastfed within the last year

  • patients with uncontrolled comorbidities, such as arterial hypertension or diabetes

  • use of immunosuppressants

  • patients who had any infection during the follow-up period, requiring the use of antibiotics

  • patients who present any adverse effects due to the antibiotics during the study

  • patients who miss follow-up assessments

  • patients who withdraw their consent at any time

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital das Clinicas Samuel Libânio, Universidade do Vale do Sapucaí Pouso Alegre MG Brazil 37550000

Sponsors and Collaborators

  • Daniela Francescato Veiga

Investigators

  • Study Chair: Daniela F Veiga, MD, PhD, Federal University of Sao Paulo

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Daniela Francescato Veiga, Associate Professor, Federal University of São Paulo
ClinicalTrials.gov Identifier:
NCT04079686
Other Study ID Numbers:
  • PosDoc
First Posted:
Sep 6, 2019
Last Update Posted:
Jul 27, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2022